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A B S T R A C T
BACkgRound: The human immunodeficiency virus (HIV) epidemic remains a major 
global public health challenge, with a total of 33.4 million people living with HIV 
worldwide. In 2008 alone, 2.7 million people were newly infected with HIV. Unfor-
tunately, the majority of patients with HIV infection worldwide live in resource poor 
areas were access to therapy is severely limited.
oBjeCTive: This review summarizes the progress noted during the recent years con-
cerning antiretroviral therapy scale up in resource-limited settings and analyzes the 
economic, social and legal framework of services already provided.
ReSulTS: The 2010 WHO report states that among 144 low- and middle-income 
countries reporting program data, eight had already achieved universal access to 
antiretroviral therapy at the end of 2009, providing treatment to at least 80% of pa-
tients in need. Furthermore, 15 countries had achieved the 80% target for coverage 
with antiretroviral prophylaxis to prevent mother-to-child transmission of HIV. An 
increase of over 1.2 million people, including women and children receiving antiretro-
viral therapy was noted by the end of 2009. Health care facilities have expanded and 
as a result, the average number of people receiving antiretroviral therapy per health 
care facility has increased. Moreover, task shifting has been applied, with promising 
results. 
ConCluSionS: Although there is considerable room for improvement, HIV programs 
have had a positive impact on equal, affordable and early antiretroviral therapy provi-
sion to those who need it most. Special approaches though, remain necessary to ad-
dress the particular circumstances and needs of those populations at greater risk for 
HIV infection. Rights-based national strategies must include special efforts to reach 
the poorest and those who are socially excluded. Interventions must be designed and 
realized in ways that ensure equity in access for all.
i n T R o d u C T i o n
Since its identification in 1981 as a novel entity, acquired immune deficiency syn-
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drome (AIDS) has infected more than 60 million and killed 20 
million people worldwide.1 The introduction of antiretroviral 
therapy in 1995-96 has led to its gradual evolution from a 
fatal disease to a chronic condition.2 Antiretroviral therapy 
has been shown to prolong survival in persons with human 
immune – deficiency virus (HIV) infection. Significant results 
have been demonstrated with the introduction of double3 as 
well as triple combination therapy.4 The remarkable increase 
in the use of these double and triple combination regimens 
has led to major declines in AIDS mortality.5 Nevertheless, 
the majority of patients with HIV infection worldwide live 
in resource poor areas were access to therapy is severely 
limited. In 2008, an estimated 33.2 million people were living 
with HIV, with 68% of all adults living with HIV, 90% of the 
world’s infected children and 76% of all AIDS deaths being 
encountered in the Sub-Saharan Africa.6 Although HIV repre-
sents a global health priority, its management and care is very 
complex and challenges the health care systems worldwide. 
Many of the countries with the highest rates of HIV infection 
have insufficient access to antiretroviral therapy. In addition 
to the actual cost of anti-HIV drugs, other major obstacles 
include the deficient health-care structures, the lack of labora-
tory facilities and health-care technology, the lack of medical 
training, as well as administrative delays. Moreover, stigma 
and discrimination continue to be experienced by people af-
fected, leading to decreased treatment adherence. Coverage 
of prevention interventions is still insufficient and the current 
economic recession has prompted even wealthy countries to 
reassess their commitment to HIV programs.7
w H e R e  d o  w e  S T A n d ?
A n T i R e T R o v i R A l  T H e R A p y  g u i d e l i n e S  – 
w H e n  T o  S T A R T 
According to the World Health Organization (WHO) 
antiretroviral therapy guidelines, all patients with HIV infec-
tion and a cluster of differentiation 4 (CD4) cell count at 
or below 350 cells/mm3 should be started on antiretroviral 
therapy. Adolescents, adults, as well as pregnant women, 
are all included, regardless of whether they have clinical 
symptoms or not.7 Guidelines from wealthy countries how-
ever, recommend even earlier initiation of anti-retroviral 
agents, at a CD4 cell count of 500 cells/mm3 or above.8 More 
specifically, updated recommendations for the management 
of HIV- infected adults in the developed world, as reported 
by the Department of Health and Human Services Panel on 
antiretroviral guidelines for adults and adolescents, include 
guidelines whose strength varies according to the number of 
CD4 cell count before treatment: 
• CD4 count <350 cells/mm3 (Ai)
• CD4 count 350 to 500 cells/mm3 (Aii)
• CD4 count >500 cells/mm3 (Biii)
Recommendations are rated with a letter (A, B, or C) that 
represents the strength of the recommendation and with the 
figures I, II, or III that signify the quality of the evidence (A: 
strong recommendation, B: moderate, C: optional; I: One or 
more randomized trials with clinical outcomes and/or validated 
laboratory endpoints, II: One or more well-designed, nonran-
domized trials or observational cohort studies with long-term 
clinical outcomes, III: Expert opinion) 
Regardless of CD4 count, initiation of therapy is strongly 
recommended for individuals with • pregnancy (Ai), • history 
of an AIDS-defining illness (Ai), • HIV-associated nephropa-
thy (Aii), • HIV/hepatitis B virus coinfection (Aii), as well as 
for • patients who are at risk of transmitting HIV to sexual 
partners (heterosexuals (Ai) or • other transmission risk 
groups (Aiii).
With regards to the consistency of the specific regimens, 
more than 20 antiretroviral drugs in 6 classes are available in 
the developed world. These 6 classes include the nucleoside/
nucleotide reverse transcriptase inhibitors (NRTIs), non-
nucleoside reverse transcriptase inhibitors (NNRTIs), protease 
inhibitors (PIs), fusion inhibitors (FIs), C-C chemokine recep-
tor type 5 (CCR5) antagonists, and integrase strand transfer 
inhibitors (INSTIs) (Table 1).9-11
The WHO guidelines for patients in developing countries 
state that first-line therapy should include a non-nucleoside 
reverse transcriptase inhibitor (NNRTI) and two nucleoside 
reverse transcriptase inhibitors (NRTI), one of which should 
be zidovudine (AZT) or tenofovir (TDF). The second-line 
therapy should consist of a ritonavir (RTV)-boosted protease 
inhibitor plus two NRTIs, one of which should be AZT or TDF, 
depending on what was used in the first-line regimen. The 
preferred protease inhibitors are ritonavir-boosted atazanavir 
(ATZ) or lopinavir/ritonavir (LPV/r).7
Overall, antiretrovirals are still underused relative to 
need in resource – limited settings, and they still reach people 
with too much delay. After the new recommendations of the 
WHO, a significant step has been made towards improving 
the efficacy of treatment in developing countries as well as 
preventing transmission of the virus. It is estimated that the 
number of people who are now in urgent need of treatment has 
increased to 14 million, raising thus the necessity for stronger 
actions and a more essential engagement towards the affected 
communities.12 
Although the use of highly active anti-retroviral therapy 
(HAART) has been proven to be very effective in prolonging 
survival of HIV infected patients, some of the drugs, especially 
the ones mostly used in poor countries, cause significant side – 
effects. Hepatotoxicity,13 osteomalacia and Fanconi syndrome, 
for example, are noted after use of tenofovir.9 Stavudine and 
navirapine have also been accused of causing long – term 
toxicities.14 The former has been correlated with pancreatitis, 
steatosis,9 peripheral neuropathy and lipoatrophy. The 2010 
WHO guidelines15 clearly recommend phasing out of the drug, 
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unfortunately though, due to low cost, stavudine containing 
regimens are still being used16 increasing the risk of lipoatrophy 
in patients who receive it.17 
p R i C e  A n d  l e g A l  F R A m e
The management of HIV infection is representative of 
what health care inequalities denote. Antiretroviral therapy 
became broadly available in developed countries in 1996, but 
it was only in 2002 when treatment programs were established 
in developing countries with the exception of Brazil, Thailand, 
Senegal and Botswana. The latter were providing antiretro-
viral therapy for adults through the public-sector health care 
TABle 1. Antiretroviral Drugs
dRug ClASS generic name / Abbreviation Formulation Fixed-dose Combination
nucleoside Reverse Transcriptase 
inhibitors (nRTis)
Abacavir / ABC Ziagen Trizivir (ABC with ZDV+3TC)
Epzicom (ABC with 3TC) 
didanosine / ddI Videx / Videx EC
emtricitabine / FTC Emtriva Atripla (FTC with EFV+TDF)
Complera (FTC with RPV+TDF)
Truvada (FTC with TDF) 
lamivudine / 3TC Epivir Combivir (3TC with ZDV) 
Epzicom (3TC with ABC) 
Trizivir (3TC with ZDV+ABC) 
Stavudine / d4T Zerit
Tenofovir disoproxil Fumarate / 
TDF
Viread Atripla (TDF with EFV+FTC) 
Complera (TDF with RPV+FTC) 
Truvada (TDF with FTC) 
Zidovudine / ZDV Retrovir Combivir (ZDV with 3TC)
Trizivir (ZDV with 3TC+ABC)
non-nucleoside Reverse  
Transcriptase inhibitors (nnRTis)
efavirenz / EFV Sustiva Atripla (EFV with TDF + FTC)
etravirine / ETR Intelence
nevirapine / NVP Viramune or
Viramine XR
Rilpivirine / RPV Edurant Complera (RPV with TDF +FTC)
protease inhibitors (pis) Atazanavir / ATV Reyataz
darunavir / DRV Prezista
Fosamprenavir / FPV /  
(a prodrug of amprenavir [APV])
Lexiva 
indinavir / IDV Crixivan
lopinavir + Ritonavir / LPV/r Kaletra
nelfinavir / NFV Viracept
Ritonavir / RTV Norvir
Saquinavir / SQV Invirase
Tipranavir / TPV Aptivus
integrase inhibitor Raltegravir / RAL Isentress
Fusion inhibitor enfuvirtide / T20 Fuzeon
CCR5 Antagonist maraviroc / MVC Selzentry
CCR5 = C-C chemokine receptor type 5.
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facilities as early as 2000. Regrettably, antiretroviral therapy 
services for children were initiated much later and continue 
to be limited.18,19
The price of antiretroviral therapy was initially prohibitive 
for patients living in poor countries since they were available 
only from originator companies. These companies controlled the 
patents on medicines which cost 10,000 – 15000 $ /person/year.20
Global political mobilization as well as vigorous action 
from non – governmental organizations (NGOs) and people 
living with HIV led to the accomplishment of a dramatic drop 
of prices of first-line antiretroviral therapy. As a result, today 
more than five million patients in the developing world have 
access to antiretroviral therapy.21 More specifically, according 
to the Global Price Reporting Mechanism, there was a decline 
of first-line drug prices for both adults as well as the pediatric 
population between 2006 and 2009 in low-income countries. 
The cost of second-line regimens also declined, still remaining 
though more expensive than first-line regimens.22
This achievement was a result of a series of events that 
started almost a decade ago. In 2000 an Indian pharmaceuti-
cal company named Cipla produced generic antiretrovirals at 
very low cost, forcing thus the big pharmaceutical companies 
to reduce their prices. It was in May 2000 when five phar-
maceutical companies announced the Accelerating Access 
Initiative, offering price discounts on antiretroviral treatment 
in developing countries. However, the prices still remained 
too high compared with the prices offered by generic manu-
facturers.23 The production of generic drugs not only brought 
the prices down, but also simplified HIV/AIDS treatment. In 
2001, Cipla produced a combination of three antiretrovirals 
into a single pill. Although the company was not the only one 
that produced fixed – dose combination pills, it was the first to 
produce the fixed – dose combination of stavudine, lamivudine 
and nevirapine, a course of therapy recommended by WHO 
at the time.24 Fixed – dose combination pills are in many ways 
advantageous both for patients and for health – care provid-
ers. Their most important benefits, the increased adherence 
and the consequent reduced incidence of drug resistance, 
have made it the basis of treatment programs in developing 
countries.25
This was of course possible because India did not have 
to comply with Trade – Related Aspects of International 
Property Rights (TRIPS) legislation at the time. Since 2005 
developing countries that are members of the World Trade 
Organization (WTO), such as India, Thailand and Brazil, 
have to obey and abide by TRIPS rules and issue patents. 
This has complicated the antiretroviral treatment’s delivery 
because although patents have expired on a number of first-line 
AIDS drugs, patents still exist on most new and second-line 
medicines. Consequently, the new drugs are only available in 
countries that are able to cover the high cost. Poor countries 
are forced to wait until their patent expires or the proprietary 
prices are decreased.26
In light of these concerns, the WTO proposed two pro-
cedures by which generic drugs under patents may be pro-
duced; the voluntary licensing and the compulsory licensing 
agreement. The former refers to a license a government, an 
individual, or an organization can request from a patent holder 
to allow generic drugs to be supplied during a public health 
emergency, either through imports or by local production. 
The drawback of voluntary licenses is that they depend on 
the goodwill of the patent holder, and can be long - lasting to 
negotiate. The compulsory license is a government license that 
enables someone other than the patent owner to copy patented 
products legally. Disadvantages include the predefined limited 
drug quantities that can be produced and the fact that the 
domestic market is the one that should be mainly supplied, 
making it difficult for poor countries that lack technological 
support to access generic drugs that are produced abroad.27
In 2003, WHO and the Joint United Nations Program 
on HIV/AIDS declared the lack of antiretroviral treatment 
to be a global public health emergency and announced the 
“3 by 5” campaign. This campaign aimed at achieving to get 
three million people on antiretrovirals by 2005. The campaign 
was supported by newly available funding from governments 
such as the Global Fund and the United States President’s 
Emergency Plan for AIDS Relief (PEPFAR) and led to access 
of generic medicines in considerable amounts.28 It is reported 
that by 2008, 95% of the global donor-funded antiretroviral 
market consisted of generics, mainly from India.29 The amount 
of generic antiretrovirals purchased by PEPFAR grew from 
15% to 89% from 2005 to 2008.30
Another way to handle intellectual property was the 
Medicines Patent Pool which was established by UNITAID, 
an organization that facilitates the purchase of drugs for HIV, 
malaria and tuberculosis (TB), hosted by WHO. It represents 
a conventional way of making voluntary licenses available, of-
fering legal assurance to all parties involved. Patent holders 
have to make licenses available so that generic companies will 
be allowed to produce low-cost generics for use in developing 
countries. Companies that receive licenses from the pool will 
pay a fee of their sales to the patent owners.31 In September 
2010, the US National Institutes of Health became the first 
patent holder to license its patents to the Medicines Patent 
Pool. Although the pool confronts challenges, it is a promising 
initiative aiming at making markets work better and facilitate 
overall distribution of HAART to those who face problems 
accessing therapy.32
The free trade agreement, another legal outline (mainly 
between India and Europe) inflicting intellectual property 
protection on drugs, became an entity of division. Some criti-
cize the free trade agreements’ provisions, as disastrous for 
public health,33 whilst others argue that intellectual property 
protection does not constitute a significant obstacle to access 
to medicines.34 The former assert that members of the Euro-
pean Free Trade Agreement have strong interests such as data 
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exclusivity and extended patent terms. This, in turn, delays the 
introduction of generic drugs and goes beyond TRIPS agree-
ment, weakening thus the distribution of medicines to people 
who need them. The latter claim that although India looses 
TRIPS flexibility, the Free Trade Agreement is not, after all, 
a major barrier to accessing therapy. 
Patients in need of antiretrovirals in the developing world 
currently have a non drug resistant form of the virus, and can 
therefore receive first-line therapy. As treatment though be-
comes more widespread, people stay on treatment for longer 
and resistance increases, the high price of second-line drugs 
is going to become a major issue.7
AvA i l A B i l i T y  A n d  H e A l T H  C A R e  FA C i l i T i e S
Health care facilities that provide antiretroviral treatment 
are important components of the antiretroviral scale-up pro-
grams. It is reported by WHO that there has been an increase 
of 36% in their number during the years 2008-2009, as provided 
by data from 99 countries. The average number of people re-
ceiving antiretroviral treatment per health care facility has also 
increased during the same time period. Interestingly, health 
care facilities in the Sub-Saharan Africa continue to treat more 
people per site than in the rest of the world.7
Scaling up treatment in endemic settings requires antiret-
roviral treatment provision by existing primary health care 
facilities wherever possible. Moving beyond the primary health 
care clinic and into the community is necessary,35,36 since this 
way the drugs are brought closer to those who need them and 
who cannot even afford their transportation to primary health 
care spots.37 Decentralization was proven to be very effective 
as it has increased adherence wherever applied. Moreover, 
studies have compared outcomes in hospitals and health care 
centers and have found no difference in the quality of care 
provided.35,38,39
The lack of specialized scientists who could offer their 
expertise to HIV infected patients in limited resource settings 
has led to the idea of ‘Task-shifting’, a program recommended 
by WHO as a way to overcome the lack of health care workers 
and the subsequent inadequate care provision. Nurses and 
clinical workers commence patients’ treatment and counselors 
provide HIV testing and adherence. The program has been 
implemented in some countries and studies report that it is 
found to be equivalent to programs run by physicians.36,40,41
Decentralized treatment and task shifting must be sup-
ported by new simplified tests. Such tests must be easily 
performed even by minimally trained health care workers. 
Viral load and CD4 measurement for example is currently 
performed by complex and expensive tests. By 2012, smaller, 
fully automated devices and by 2013, ‘dipstick’- type CD4 
tests and even simpler viral load tests will be available. This 
way, adherence problems, as well as treatment failure will be 
detected on time and consequently, resistance shall be avoided. 
Moreover, a new molecular TB test is expected by 2011 which 
will be able to detect TB much more easily among people who 
are infected both with TB and HIV.42
Another major issue of concern in low and middle- income 
countries is the management of drug stock-outs. All the sectors 
involved must be in close collaboration so as to distribute and 
relocate potential abundance of drugs as needed. As reported 
by WHO, 36 of the 94 countries reported at least one or more 
stock-out of antiretroviral drugs in health care facilities in 
2009, compared to 31 out of 90 countries in 2008 and 25 out 
of 66 countries in 2007.7
p R o g R e S S  o F  A C C e S S  T o  A n T i R e T R o v i R A l 
T H e R A p y
An increase of over 1.2 million people receiving antiretro-
viral treatment was noted at the end of 2009, worldwide. The 
greatest increase was observed in Sub-Saharan Africa, while 
the smallest was monitored in Latin America, possibly due 
to the already achieved high levels of coverage of most large 
countries of the region. Zimbabwe is being reported to have 
raised the number of patients receiving antiretroviral treat-
ment by 50% between December 2008 and 2009.7
The global fund to fight AIDS, tuberculosis and ma-
laria and the US President’s emergency plan for AIDS relief 
(PEPFAR) remained the two major international sources of 
funding for antiretroviral treatment programs in low- and mid-
dle- income countries in 2009. Based on WHO 2010 guidelines, 
eight low- and middle- income countries had already achieved 
universal access to antiretroviral treatment, that is providing 
it to at least 80% of people in need. 
With regards to children, there has been an increase of 29% 
in antiretroviral treatment uptake during 2009. Overall antiret-
roviral therapy coverage however, was lower among children 
than among adults in low and middle- income countries. This 
is due to the fact that sub-Saharan Africa accounts for 89% 
of children needs, but has an estimated coverage rate of 26%. 
Antiretroviral coverage was higher for women, estimated at 
39% compared with 31% among men.7
According to WHO 2011 news release, there has been 
globally an increase in access to HIV services which has led 
to 15% reduction of new infections (Figure 1).43
A total of 56% coverage for antiretroviral therapy and 64% 
uptake of preventing mother-to-child transmission (PMTCT) 
services have been reported in Eastern and Southern Africa. 
In Asia, 4.8 million people receive antiretroviral treatment, 
half of them living in India. Interestingly, a dramatic growth 
of HIV over the past decade (>250%) has been noted in 
Eastern Europe and Central Asia with >90% of the people 
affected living in Russia and Ukraine. Statistics report that 
Latin America and the Caribbean count for 1.5 million and 
200000 people living with HIV respectively.43
p R e v e n T i o n  o F  H i v  d R u g  R e S i S T A n C e
Resistance to HIV drugs is inevitable due to the virus’ high 
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mutation rate and recombination and may lead to weakening 
of the significant gains of antiretroviral treatment. Hence, 
monitoring of the viral resistance and maintenance of the ef-
fectiveness of first- and second-line regimens are of outmost 
importance. 
A recent review of studies conducted in sub-Saharan Africa 
and India reports a high frequency of resistance mutations 
among patients failing first-line therapy,44 whereas most re-
ports from low- and middle-income countries depict low rates 
of transmitted resistance.45
A global strategy for the prevention and assessment of 
HIV drug resistance has been implemented by WHO and the 
Global HIV Drug Resistance Network (HIVResNet), aiming 
at improving surveillance of HIV drug resistance with regular 
approaches. WHO recommends that countries should base 
their strategy for the prevention and assessment of HIV drug 
resistance on three key considerations: (1) scheduled monitor-
ing of “early warning indicators” of HIV drug resistance, (2) 
surveys to monitor the emergence of HIV drug resistance in 
populations receiving antiretroviral therapy, and (3) surveys to 
evaluate transmitted HIV drug resistance in recently infected 
populations. By 2010, over 60 countries had implemented one 
or more elements of the proposed strategy. WHO facilitated 
achievement of country goals, by approving national, regional 
and specialized HIV drug resistance testing laboratories and 
by December 2009, 24 HIV drug resistance testing laboratories 
had been accredited.7
Nevirapine (NVP) has been widely used as single dose 
prophylaxis at the onset of labor,46,47 however even a single dose 
frequently induces viral resistance.48,49 Aiming at reducing viral 
resistance as well as the risk of vertical HIV-1 transmission, 
the 2010 WHO guidelines50 for the prevention of mother-to-
child transmission (PMTCT), supported by findings of recent 
studies, recommend use of HAART during pregnancy as well 
as after delivery.51,52
m o T H e R S  A n d  C H i l d R e n
Mother-to-child transmission (MTCT) remains the ma-
jor route of HIV infection among children.53 Prevention of 
mother-to–child transmission (PMTCT) programs, particularly 
in resource-limited settings, need to be scaled up. Mother-to-
child transmission rates in the United States and Europe are 
below 2% due to wide coverage with HAART.54 Unfortunately, 
in contrast to the developed world, only 45% of HIV-positive 
women in low and middle income countries received antiret-
roviral prophylaxis for PMTCT in 2008.53
Uptake of PMTCT services in resource-limited settings 
can be advanced by utilizing novel options such as integrat-
ing PMTCT services into existing maternal and child health 
structures, addressing information gaps as well as activating 
the people in charge.55
According to 2010 WHO report, HIV services for women 
and children have expanded in 2009. An estimated 26% of all 
pregnant women in low- and middle income countries received 
an HIV test in 2009 compared to 21% in 2008, and 53% of 
pregnant women living with HIV received antiretroviral 
drugs to reduce the risk of transmitting HIV to their infants 
compared to 45% in 2008. Sub-Saharan Africa is the region 
FiguRe 1. WHO Progress Report Summary 2011 (p.18/28)43 
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which has around 91% of the pregnant women in need of 
antiretroviral drugs; the coverage in 2009 was 54%.7
In the pediatric population, an increase of 29% of chil-
dren less than 15 years of age receiving antiretrovirals was 
noted in 2009 compared with 2008. These children repre-
sented an estimated 28% of all children less than 15 years 
estimated to need treatment in low- and middle-income 
countries, up from 22% in 2008 and 7% in 2005.7 Overall, 
antiretroviral therapy coverage among children in low- and 
middle-income countries was lower than that among adults. 
Moreover, only 15% of children born from HIV positive 
mothers were tested for HIV within the first two months of 
life, in 54 reporting countries.7
The 2010 revised guidelines on prevention of mother-to-
child transmission of HIV propose major changes for earlier 
antiretroviral therapy for a larger group of HIV-positive preg-
nant women (CD4 350 or stage 3 or 4 disease). In addition, the 
revised guidelines now suggest the provision of antiretrovirals 
to the mother or child to reduce the risk of HIV transmission 
during breastfeeding wherever this is judged to be the safest 
feeding option. Updated pediatric antiretroviral treatment 
guidelines now advise that all HIV-positive children less than 
24 months of age should be started on antiretroviral therapy 
and that children older than 24 months of age must be initi-
ated on treatment depending on age-specific CD4 cell count 
thresholds.7
Greater efforts are needed to scale up early testing of 
HIV-exposed infants and further incorporate HIV interven-
tions with services for maternal, newborn and child health.
H i v  R e l A T e d  T u B e R C u l o S i S  ( T B )
HIV-related TB remains an important universal challenge. 
In 2008, 1.4 million out of 9.4 million people living with TB 
worldwide were co-infected with HIV. Statistics report that 
26% of deaths in people with HIV can be attributed to TB.7 
Data show that the risk for TB is 20–37 times higher in people 
living with HIV than in the general population, depending 
on the prevalence of HIV in the population. The majority of 
people living with HIV and TB in the world are encountered 
in Sub-Saharan Africa.56
A total of 58 countries reported at least one case of 
extensively drug-resistant TB in 2008, with Eastern Europe 
and Central Asia being the regions more severely affected by 
multidrug-resistant TB. Difficulties and delays in diagnosis, 
lack of access to antiretroviral treatment and complications 
of concurrent treatment for both conditions, as well as inad-
equate TB infection control measures, all account for possible 
explanations for the fact that people living with HIV are at 
higher risk for drug-resistant forms of TB.57,58
Various forms of integrated HIV and TB services have 
been applied in several countries with promising results. Sci-
entific studies support that antiretroviral therapy can reduce 
the incidence of TB, and may diminish morbidity and mortality 
from TB. Antiretroviral therapy has been characteristically 
shown to reduce TB incidence by up to 90% at the individual 
level and by 60% at the population level.59 Every person with 
symptoms and signs of TB and every patient with confirmed 
TB should therefore be tested for HIV. 
i n T e R v e n T i o n S  F o R  H i v  p R e v e n T i o n
Maximizing the health sector’s contribution to HIV pre-
vention is vital and includes interventions meant for people 
regardless of HIV status (presumed HIV-negative) and for 
people living with HIV. A set of specific interventions such as 
counseling on safer sex, enabling people to be informed about 
their HIV status and educating on transmission prevention, 
have been proposed for most vulnerable populations such as 
injecting drug users, men who have sex with men, transgender 
persons, sex workers, prisoners, pregnant women, infected 
mothers and health-care workers.60
Male circumcision is suggested by WHO and the Joint 
United Nations Program on HIV/AIDS (UNAIDS) as an 
additional intervention to reduce the risk of heterosexual 
transmission of HIV to men. A reduction in HIV transmission 
among men that were circumcised has been reported by clinical 
trials.61-63 Circumcision has also been reported to reduce the 
risk of HIV-1 male to female transmission and to decrease 
the incidence of multiple infections due to high-risk human 
papilloma virus (HPV). 
Finally, the rapid identification and treatment of sexually 
transmitted infections is considered to be a key element in 
controlling the spread of HIV as sexually transmitted infections 
synergistically increase the risk of HIV transmission. Avail-
ability, safety and accessibility of blood and blood products 
have also been an issue of concern. As proposed by WHO, 
all activities related to blood collection, testing, processing, 
storage and distribution should be coordinated at national 
level through an appropriate legal outline.7
New biomedical prevention technologies, such as microbi-
cides, and pre-exposure as well as post-exposure prophylaxis 
(PEP) with antiretroviral drugs and vaccines, may expand 
considerably the contribution to HIV prevention. Interestingly, 
a tenofovir (TDF)-containing vaginal microbicide was found 
by the Centre for the AIDS Program of Research in South 
Africa (CAPRISA) to have a statistically significant protective 
effect against HIV.64
Substantial progress has been made in establishing preven-
tion services in many countries. In 2008 however, the number 
of new infections was still bigger than the number of people 
started on treatment. This emphasizes the importance of 
further expanding prevention measures.7 Studies referring to 
serodiscordant couples in Africa, report that strategic use of 
pre-exposure prophylaxis and antiretroviral therapy reduce 
HIV-1 transmission in a cost – effective way.65,66 
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Surveillance and evaluation of procedures and outcomes 
are needed in the application of antiretroviral therapy scaling 
up, as they provide a more adequate understanding on whether 
programmatic responses are appropriate or not and lead to 
implementation of changes whenever necessary. Countries all 
around the world are continuously improving the monitoring 
and reporting of program retention on antiretroviral therapy. 
Fox and Rosen report an increased rate of retention (70% - 
77% at 24 months and 65% - 72% at 36 months), in patients 
living in Sub-Saharan Africa. This improvement could lead to 
a change in the criteria for initiation of antiretroviral therapy, 
as initiation of antiretrovirals at a high CD4 cell count has 
been associated with lower mortality and improved treatment 
outcomes.67
Patients diagnosed as HIV positive however, may not start 
therapy or may start after having reached eligibility levels. 
Hence, it is very important apart from improving retention, 
to pay attention to the attrition of patients in HIV care before 
initiation of antiretroviral therapy.68 Evaluation of the impact 
of antiretroviral therapy on mortality is critical to guarantee the 
continued political commitment necessary to sustain a lifelong 
intervention. A systematic analysis of worldwide mortality 
among adults aged 15–59 years from 1970 to 2010 showed that 
mortality increased considerably in sub-Saharan Africa in the 
late 1980s and began to decline since 2005, a trend that coin-
cides with an increase in access to antiretroviral treatment.69,70
Advancing the scale up of antiretroviral therapy has also 
variably benefited other health-care services. In high income 
countries an impact of antiretrovirals on reducing morbidity 
and use of hospital services has been documented.71 Moreo-
ver, a reduction in the burden of care placed on overwhelmed 
health care systems and a decrease in mortality among health 
care workers is noted as a result of antiretroviral therapy ap-
plication in countries highly affected by the epidemic.72
C o n C l u S i o n S
Over the past 10 years, a number of key strategies have 
been identified to support scale up of HIV treatment, improve 
quality of care, and reduce costs. Although many challenges 
are ahead, the fact is that millions of people are alive today 
as a result of antiretroviral therapy.
Integrating services and strategies can improve equity, 
access and coverage and may also improve the quality and effi-
ciency of care. In order to carry out these plans, HIV programs 
must be executed within a primary health-care framework 
capable of providing efficient services that address multiple 
patient needs through continuous care. These include services 
for maternal and child health, management of tuberculosis and 
sexually transmitted infections. Strong actions are required to 
reduce HIV transmission and to meet the needs of groups at 
higher risk for HIV infection. Focused efforts are needed to 
remove punitive laws and create enabling legal environments 
that address the human rights violations currently blocking 
effective AIDS responses. The involvement of communities 
in program management is necessary in order to ensure the 
adequacy of interventions delivered.
The schedule of the global HIV response remains un-
doubtedly incomplete. Every day, thousands of people are 
still being infected and dying due to lack of access to preven-
tion, treatment and care. The sooner high-quality services 
are scaled up, the larger will be the social and economic gains 
from fewer infections, lower mortality and better quality of 
life for those infected. The strengthening of the health care 
systems is essential to guarantee individuals a life-long therapy 
even in the rural areas where the majority of people in need 
of treatment live. Reducing inequity is a global responsibility. 
The international community has an obligation to mobilize 
resources to support the low-income nations of the world and 
the civil society has the duty to ensure that scientific, social 
and political leaders fulfill their commitments on a local, 
regional and global basis.
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